MW Sarepta Therapeutics stock falls after DMM patient dies of liver failure
Sarepta Therapeutics Inc.'s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug Elevidys, which is used to treat Duchenne muscular dystrophy.
While liver failure is a known possible side effect of Elevidys, it had not yet been reported until now, Sarepta (SRPT) said.
"Acute liver failure leading to death represents a severity of acute liver injury notpreviously reported for Elevidys, which to date has been used to treat more than 800 patients inclinical trials or as a prescribed therapy," the company said.
Prior to Tuesday's moves, Sarepta's stock was down 16.7% so far in 2025, while Nasdaq COMP has dropped 7.8%.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
March 18, 2025 09:02 ET (13:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.